AusCann Group Holdings Ltd

AC8

AU000000AC89

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:35 2022-08-31 am EDT			5-day change	1st Jan Change
0.04 ^AUD	-4.76%		-.--%	-.--%

Apr. 03	AusCann Group Holdings Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	CI
Jan. 25	AusCann Group Seeks to Raise Up to AU$1 Million Via Share Purchase Plan	MT

AusCann Group Holdings Ltd Appoints Nick Woolf as Chief Executive Officer

August 04, 2020 at 06:29 pm EDT

AusCann Group Holdings Limited announced Nick Woolf as the new Chief Executive Officer (CEO) effective immediately. Nick joins AusCann after some 25 years' experience in the Investment Banking and Life Sciences industries both in Australia and internationally. His previous roles include CEO of Proteolytics, Chief Business Officer of Suda Pharmaceuticals and Chief Financial Officer of PYC Therapeutics.

Latest news about AusCann Group Holdings Ltd

AusCann Group Holdings Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	Apr. 03	CI
AusCann Group Seeks to Raise Up to AU$1 Million Via Share Purchase Plan	Jan. 24	MT
AusCann Group Holdings Ltd Announces Change of Company Address	Jan. 02	CI
AusCann Group Holdings Limited Announces Company Secretary Changes	Jan. 01	CI
Auscann Group Appoints Nonexecutive Chair	Nov. 30	MT
AusCann Group Holdings Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Auscann's Expanded Partnership with European Cannabis to Bring EU GMP Certified Medicinal Cannabis to Aus, NZ	23-07-30	MT
AusCann Group Holdings Limited Announces Executive Changes	23-06-28	CI
Auscann Group Settles Sale of Facility in Wangara, Western Australia	23-06-14	MT
Auscann Group Selling Western Australian Premises for Nearly AU$7 Million	23-04-04	MT
Layton Mills and Margaret Curtis agreed to acquire 52% stake in CannPal Animal Therapeutics Limited from AusCann Group Holdings Ltd for AUD1.	23-03-09	CI
AusCann Group Holdings Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
AusCann Group Holdings Ltd Announces Resignation of Krista Bates as Non-Executive Director	23-01-02	CI
AusCann Group Holdings Ltd Auditor Raises 'Going Concern' Doubt	22-09-29	CI
AusCann Group CEO Resigns	22-09-12	MT
AusCann Group Holdings Ltd Announces the Resignation of Layton Mills as Chief Executive Officer	22-09-12	CI
Auscann Group Enters Secured Loan Facility with European Cannabis	22-09-09	MT
AusCann Group Holdings Ltd Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-31	CI
AusCann Group Holdings Ltd Appoints Chris Mews as Chief Financial Officer	22-08-12	CI
AusCann Group Holdings Ltd Enters Secured Commercial Loan Facility with Eurocann	22-04-28	CI
AusCann Group Holdings Limited Enters Binding Term Sheet with European Cannabis Corporation Ltd	22-04-28	CI
Auscann Group CFO to Step Down in April	22-03-11	MT
AusCann Group Holdings Ltd Announces Resignation of Charles Altshuler as Chief Financial Officer, Effective April 7, 2022	22-03-10	CI
AusCann Group Holdings Ltd Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-28	CI
Australian Shares Rebound on Improving Business Confidence	22-02-08	MT

Chart AusCann Group Holdings Ltd

Duration

Period

More charts

Company Profile

AusCann Group Holdings Limited is an Australia-based company focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. Its products include Neuvis, CPAT-01, DermaCann and MicroMax. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol (THC) and cannabinoids (CBD) whole plant extracts in a proprietary ratio to target pain and inflammation in dogs. DermaCann is a CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. The product is a liquid oral oil formulation containing CBD in a patented combination with other bioactive lipids designed to target inflammation and immune modulation pathways. MicroMAX is an encapsulation technology for use in the field of animal therapeutics. Its subsidiaries include AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AUSCANN GROUP HOLDINGS LTD	-.--%	11.43M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B